Mantle Cell Lymphoma Market Size and Forecast 2026-2035
The global mantle cell lymphoma market is USD 2.51 billion in 2025 and is forecast to reach USD 4.53 billion by 2035, expanding at a CAGR of 6.1% during 2026-2035.
The underlying clinical market is also changing much faster than the legacy segmentation suggests. FDA approved acalabrutinib plus bendamustine and rituximab for previously untreated transplant-ineligible MCL in January 2025, establishing the first U.S. BTK-inhibitor-based frontline approval in the disease.
Europe subsequently approved an ibrutinib-containing frontline regimen for transplant-eligible patients in July 2025 based on the Phase III TRIANGLE study, reinforcing the movement of BTK inhibition from relapsed disease into initial treatment.
Relapsed disease is equally dynamic. FDA converted Tecartus to traditional approval for relapsed/refractory MCL on April 1, 2026, while sonrotoclax/Beqalzi became the first FDA-approved BCL-2 inhibitor specifically for MCL on May 13, 2026.
Global Mantle Cell Lymphoma Market Highlights
- 2025 Market Size: USD 2.51 Billion
- 2035 Forecast Market Size: USD 4.53 Billion
- CAGR, 2026-2035: 6.1%
- Largest Region: North America - 40.2% share
- Fastest-Growing Region: Asia-Pacific
- Leading Treatment Category: Targeted Therapy - 45.8% share
- Leading Route: Oral - 49.0% modeled share
- Largest Treatment Setting: Frontline MCL
- Primary Innovation Themes: BTK-first frontline therapy, chemotherapy-free combinations, CAR-T earlier in relapse, BCL-2 inhibition, bispecific antibodies, TP53-directed strategy and MRD-guided transplant avoidance
Mantle Cell Lymphoma Market Definition
Mantle cell lymphoma is a B-cell non-Hodgkin lymphoma characterized in most cases by abnormal cyclin D1 expression associated with the IGH::CCND1 rearrangement, classically t(11;14).
NCI states that more than 95% of cases are cyclin D1-positive and that MCL cells are typically CD5-positive and CD20-positive.
MCL is biologically heterogeneous.
NCI distinguishes a more indolent non-nodal leukemic form, representing roughly 20% of patients, from the more common aggressive nodal form. Prognosis is additionally influenced by age, performance status, tumor burden, LDH, extranodal disease, proliferation indices, and particularly TP53 status.
The disease typically affects older adults. Current J&J clinical information places global incidence at 1-2 cases per 100,000 people per year, notes a higher prevalence in men, and describes a median diagnostic age around 65 years.
White-Space Opportunity: Frontline MCL Is Moving Toward Chemotherapy-Free and Transplant-Light Treatment
For many years, the commercial MCL market was divided relatively simply:
chemoimmunotherapy first → BTK inhibitor after relapse → CAR-T after additional progression.
That model is being dismantled.
The first major change is the movement of BTK inhibitors into frontline treatment.
FDA approved Calquence plus bendamustine and rituximab in January 2025 for previously untreated adults who are not candidates for autologous stem-cell transplantation. The ECHO study showed median progression-free survival of 66.4 months with acalabrutinib plus BR versus 49.6 months with BR alone, corresponding to a 27% reduction in progression or death risk.
Europe has moved in parallel for younger transplant-eligible patients.
The European Commission approved an ibrutinib-containing frontline regimen in July 2025 based on TRIANGLE. The trial evaluated 870 patients and showed that an ibrutinib-containing strategy without autologous transplantation could improve outcomes while avoiding the toxicity and resource burden of transplant.
The next step is removing chemotherapy as well.
On June 30, 2026, BeOne Medicines reported positive Phase III MANGROVE topline results for zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated MCL. The chemotherapy-free regimen reduced the risk of progression or death by 43%, with global regulatory submissions planned for the second half of 2026.
This creates a major white-space opportunity:
frontline MCL may evolve from chemotherapy + transplant toward oral BTK-based, antibody-based and biomarker-adapted treatment.
Commercial value would shift away from one-time intensive chemotherapy and transplant episodes toward prolonged targeted drug treatment.
Mantle Cell Lymphoma Market Key Takeaways
- Targeted therapy has expanded materially beyond the 37.8% share reported on the current DMI page. The refreshed model estimates BTK and other targeted therapies at 45.8% of 2025 market revenue, reflecting the movement of acalabrutinib into first-line U.S. treatment and broader use of BTK inhibitors across the disease course.
- CAR-T is becoming an increasingly important high-value segment. Breyanzi received FDA approval for MCL in May 2024, while Tecartus' original accelerated approval was converted to traditional approval in April 2026.
- BCL-2 inhibition has become a new commercial category. FDA's May 13, 2026 accelerated approval of sonrotoclax/Beqalzi created the first approved BCL-2 therapy specifically for adults with relapsed/refractory MCL after a BTK inhibitor. The pivotal study produced a 52% response rate and median response duration of 15.8 months.
- Bispecific antibodies represent the next likely market entrant. Roche's Phase III GLOBRYTE trial is actively recruiting and compares glofitamab against investigator's choice in relapsed/refractory MCL, with primary completion currently estimated for August 2027.
- TP53 status is becoming a strategic treatment-selection variable because NCI notes that standard chemoimmunotherapy is particularly ineffective in TP53-altered disease and that BTK inhibitors, CAR-T, bispecifics and BCL-2 strategies are more relevant in this high-risk population.
Mantle Cell Lymphoma Market Trends
BTK Inhibitors Are Moving from Relapse to Frontline Therapy
BTK inhibition is now the central targeted mechanism in MCL.
NCI lists acalabrutinib, zanubrutinib, ibrutinib, and pirtobrutinib among the principal BTK inhibitors used across contemporary MCL treatment strategies.
The commercial significance of frontline use is substantial.
Acalabrutinib plus BR became FDA-approved in untreated transplant-ineligible MCL in January 2025. The same FDA action also converted acalabrutinib's previously treated MCL indication from accelerated to traditional approval.
In Europe, ibrutinib entered frontline transplant-eligible therapy in July 2025 based on TRIANGLE.
Zanubrutinib could further accelerate the transition. Phase III MANGROVE showed a 43% reduction in progression/death risk with zanubrutinib plus rituximab compared with BR in untreated disease, according to topline results announced in June 2026.
Autologous Stem-Cell Transplant Is Losing Its Automatic Role
For decades, fit younger patients often received intensive cytarabine-containing induction followed by high-dose therapy and autologous stem-cell transplant.
That paradigm is now being questioned.
NCI's current MCL treatment review summarizes TRIANGLE and notes that transplant did not add efficacy to the ibrutinib-containing treatment strategies while increasing toxicity.
MRD data reinforce this direction.
NCI summarizes ECOG 4151, in which patients who became MRD negative after initial treatment showed no difference in three-year overall survival whether they received autologous transplant or proceeded with rituximab maintenance without transplant.
This creates a major market shift from age-based transplant eligibility toward response- and MRD-adapted treatment intensity.
CAR-T Is Becoming an Earlier Relapse Option
Tecartus established CAR-T as a major treatment for relapsed/refractory MCL.
FDA converted its MCL indication from accelerated to traditional approval in April 2026 after completion of confirmatory ZUMA-2 requirements.
Gilead/Kite states that the updated evidence supports Tecartus as a potential second-line option and includes data in patients who had not previously received BTK inhibitors.
Breyanzi created another CD19 CAR-T option when FDA approved it in May 2024 for adults with relapsed/refractory MCL after at least two prior systemic therapies including a BTK inhibitor.
In the FDA efficacy population, Breyanzi produced an 85.3% overall response rate and 67.6% complete response rate.
Competition between Tecartus and Breyanzi is therefore shifting CAR-T from a last-resort concept toward a strategic sequencing decision after initial targeted therapy.
BCL-2 Inhibition Creates a New Post-BTK Treatment Class
One of the most important developments of 2026 is the entrance of BCL-2 inhibition into approved MCL therapy.
On May 13, FDA granted accelerated approval to sonrotoclax/Beqalzi for adults with relapsed/refractory MCL after at least two prior systemic therapy lines including a BTK inhibitor.
The registration study evaluated 103 efficacy patients previously treated with anti-CD20 therapy and a BTK inhibitor.
The overall response rate was 52%, and median duration of response reached 15.8 months.
This creates an oral post-BTK option that competes with non-covalent BTK inhibition and CAR-T while also opening combination opportunities.
FDA's confirmatory requirement specifically calls for a randomized trial of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo, showing how BCL-2 and BTK inhibition may ultimately become combined rather than sequential strategies.
Pirtobrutinib Keeps BTK Targeting Relevant After Covalent BTK Failure
Pirtobrutinib/Jaypirca is a non-covalent BTK inhibitor designed to maintain BTK pathway inhibition after prior covalent BTK therapy.
Its U.S. MCL indication remains an accelerated approval for adults with relapsed/refractory disease after at least two systemic treatments including a BTK inhibitor.
The commercial significance is that failure of first-generation or second-generation covalent BTK inhibition no longer necessarily ends BTK-directed treatment.
Post-BTK MCL is therefore increasingly segmented by whether clinicians select:
non-covalent BTK inhibition, BCL-2 inhibition, CAR-T, bispecific antibodies or clinical trials.
Bispecific Antibodies Could Challenge CAR-T in Relapsed MCL
CD20×CD3 bispecific antibodies have transformed other B-cell lymphomas and are now advancing in MCL.
Roche's GLOBRYTE Phase III study is directly comparing glofitamab monotherapy with bendamustine-rituximab or lenalidomide-rituximab in relapsed/refractory MCL. The study remained recruiting as of July 2026.
Bispecific antibodies could offer a major logistical advantage over CAR-T because they are manufactured in advance rather than individually produced from each patient's T cells.
The trade-off will center on depth and durability of response versus convenience, treatment frequency, CRS management, and cumulative toxicity.
High-Risk TP53 Disease Is Becoming a Separate Commercial Segment
TP53 abnormalities are among the most important negative prognostic biomarkers in MCL.
NCI states that conventional chemoimmunotherapy is particularly ineffective for patients with TP53 pathogenic variants and highlights BTK inhibitors, CAR-T, bispecific antibodies and BCL-2 inhibition as more relevant approaches.
This has significant implications for product development.
Instead of designing trials for all-comer MCL, developers are increasingly investigating high-risk groups defined by TP53 alterations, blastoid morphology, high proliferation and other molecular features.
The NCI-listed WINDOW-4 study, for example, specifically recruits high-risk newly diagnosed MCL and uses BTK inhibitor plus rituximab followed by glofitamab consolidation, with MRD negativity as a major endpoint.
MRD and ctDNA Are Moving Toward Treatment Decisions
The next stage of personalization is not simply choosing the right drug.
It is deciding how long treatment is required.
NCI's current review describes MRD-guided transplant evidence, while new trials are increasingly incorporating circulating tumor DNA and next-generation sequencing MRD into frontline treatment design.
A newly registered 2026 study of orelabrutinib, obinutuzumab and short-course venetoclax uses plasma ctDNA-based MRD negativity as a primary endpoint, illustrating how fixed-duration therapy may become linked to molecular response rather than predetermined indefinite treatment.
This could eventually shift the market from treat-until-progression BTK therapy toward MRD-adapted fixed-duration combinations.
Mantle Cell Lymphoma Market Scope
| Metrics | Details |
| Historical Years | 2023-2024 |
| Base Year | 2025 |
| 2025 Market Size | USD 2.51 Billion |
| Forecast Period | 2026-2035 |
| 2035 Market Size | USD 4.53 Billion |
| CAGR | 6.10% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Treatment Type | Targeted Therapy, Chemoimmunotherapy, CAR-T, BCL-2 Therapy, Other/Emerging Treatments |
| Targeted Therapy | Covalent BTK Inhibitors, Non-Covalent BTK Inhibitors, BCL-2 Inhibitors, Immunomodulatory/Other Targeted Agents |
| Treatment Setting | Frontline, Relapsed/Refractory, Post-BTK/Heavily Pretreated |
| Route | Oral, Intravenous, Cellular/Other |
| End User | Hospitals/Cancer Centers, Specialty Hematology Clinics, Academic/Cell-Therapy Centers, Others |
| North America | U.S., Canada, Mexico |
| Europe | Germany, UK, France, Italy, Spain, Rest of Europe |
| Asia-Pacific | China, Japan, South Korea, India, Australia, Rest of Asia-Pacific |
| Latin America | Brazil, Argentina, Rest of Latin America |
| Middle East & Africa | Saudi Arabia, UAE, Israel, South Africa, Rest of MEA |
| Revenue Units | USD Billion |
| Report Insights | Market Size, Forecast, BTK Inhibitors, CAR-T, BCL-2 Inhibition, Bispecifics, TP53, MRD, Treatment Sequencing, Regional Analysis, Competitive Landscape |
Mantle Cell Lymphoma Market Disruption Analysis
The first major disruption is BTK migration into frontline therapy.
Calquence's January 2025 U.S. approval and Imbruvica's July 2025 European frontline expansion moved targeted therapy into treatment-naïve MCL rather than reserving it primarily for relapse.
The second disruption is chemotherapy de-escalation.
MANGROVE's positive Phase III results suggest that zanubrutinib plus rituximab could provide a chemotherapy-free frontline option if regulatory submissions result in approval.
The third disruption is transplant de-escalation.
TRIANGLE and MRD-guided ECOG 4151 data challenge the assumption that every fit, younger responding patient requires autologous transplantation.
The fourth disruption is post-BTK competition.
Pirtobrutinib, sonrotoclax, Tecartus and Breyanzi create different pathways after covalent BTK failure, and glofitamab could add an off-the-shelf T-cell engager.
The fifth disruption is molecular treatment duration.
MRD and ctDNA could eventually determine whether patients discontinue treatment, receive transplantation or intensify therapy, changing both clinical outcomes and lifetime treatment revenue.
Mantle Cell Lymphoma Market Dynamics
Aging Populations Support Diagnosis Growth
MCL occurs predominantly in older adults, with a median diagnostic age near 65 and a higher prevalence among men.
This demographic profile supports continued diagnosis growth as populations age across North America, Europe and several Asia-Pacific markets.
Long-Duration Oral Therapy Increases Revenue Per Patient
BTK inhibitors are generally orally administered and may continue until progression or unacceptable toxicity in several treatment settings.
This converts MCL from a market once heavily dependent on episodic chemotherapy into one increasingly influenced by prolonged pharmacy expenditure.
Oral therapy also shifts more treatment away from infusion centers and toward specialty-pharmacy distribution.
Multiple Relapses Create Sequential Treatment Demand
MCL remains difficult to cure with standard therapy, and relapse is common.
NCI notes that most patients eventually relapse even though outcomes have improved considerably.
The expansion of distinct mechanisms-covalent BTK inhibition, non-covalent BTK inhibition, BCL-2 inhibition, CAR-T and bispecific antibodies-means one patient may generate several high-value treatment episodes across the disease course.
TP53 Creates Persistent Unmet Need
Patients with TP53-altered, blastoid or highly proliferative disease continue to have disproportionately poor outcomes.
NCI specifically identifies standard chemoimmunotherapy as particularly ineffective for TP53-mutated disease.
This supports premium drug development in high-risk molecularly selected populations even though MCL itself remains relatively rare.
CAR-T Infrastructure Limits Broad Adoption
CAR-T requires leukapheresis, manufacturing, lymphodepletion, specialized infusion centers and expertise managing cytokine release syndrome and neurological toxicities.
FDA's Breyanzi MCL approval includes REMS-related safety requirements, and Tecartus labeling similarly reflects serious immune-mediated toxicity.
These requirements constrain access outside major academic and comprehensive cancer centers.
Treatment Cost and Long-Term Toxicity Remain Important Restraints
The increasing availability of prolonged oral targeted therapy, multi-agent combinations and cell therapy improves disease control but increases lifetime treatment expenditure.
BTK inhibitors can be associated with infections, bleeding and cardiac effects, while CAR-T introduces CRS, neurological toxicity and prolonged cytopenias.
BCL-2 therapy adds risks including tumor lysis syndrome, infection and neutropenia, as reflected in the Beqalzi prescribing framework.
Mantle Cell Lymphoma Market Segment Analysis
Targeted Therapy Leads with 45.8%
Targeted therapy is estimated to account for 45.8% of global MCL market revenue in 2025, equal to roughly USD 1.15 billion.
This represents a meaningful increase from the 37.8% targeted-therapy share reported on the existing DataM Intelligence page.
BTK inhibitors account for the largest portion.
Acalabrutinib now has an approved U.S. role in both previously treated and previously untreated transplant-ineligible MCL, while ibrutinib maintains important international MCL indications and pirtobrutinib provides a non-covalent option after prior BTK therapy.
Targeted therapy should continue gaining share as zanubrutinib pursues frontline regulatory expansion and BCL-2 combinations enter the market.
Chemoimmunotherapy Represents 28.7%
Chemoimmunotherapy is estimated to account for 28.7% of 2025 market revenue, around USD 720 million.
Bendamustine plus rituximab remains an important frontline regimen, particularly in older patients, while cytarabine-containing regimens continue to be used in fitter populations.
However, its share is expected to decline gradually.
Calquence plus BR adds targeted therapy onto chemotherapy rather than eliminating it, but MANGROVE's chemotherapy-free zanubrutinib-plus-rituximab results suggest that future frontline treatment could increasingly bypass cytotoxic chemotherapy.
CAR-T Accounts for 14.2%
CAR-T is estimated to contribute 14.2% of 2025 treatment-market value, equal to about USD 356 million.
Its revenue share is much greater than its treated-patient share because of high per-patient treatment value.
The segment includes Tecartus and Breyanzi.
Breyanzi's FDA MCL approval produced an 85.3% response rate and 67.6% complete response rate in its key efficacy population.
Tecartus received full FDA approval in April 2026 and can increasingly be considered earlier in relapsed disease.
BCL-2 and Other Emerging Treatments Represent 11.3%
BCL-2 therapy, immunomodulatory therapy, emerging bispecific antibodies and other treatment approaches collectively account for an estimated 11.3%, USD 284 million.
Sonrotoclax now gives this segment a dedicated FDA-approved MCL product following its May 2026 accelerated approval.
Bispecific antibodies remain investigational in MCL, but Phase III glofitamab development could materially expand this category.
Frontline MCL Generates 54.5% of Revenue
Frontline treatment is estimated to account for around 54.5% of 2025 market value.
The segment is becoming more commercially important as targeted drugs move earlier in treatment.
Calquence's U.S. frontline indication and Imbruvica's new European frontline indication both expand the drug-treated value of newly diagnosed MCL.
Zanubrutinib could further enlarge this segment if MANGROVE supports regulatory approvals.
Relapsed/Refractory MCL Represents 29.5%
Conventional relapsed/refractory treatment contributes an estimated 29.5% of market revenue.
This segment includes covalent BTK therapy, non-covalent BTK therapy, anti-CD20-based combinations and CAR-T selection.
Post-BTK and Heavily Pretreated MCL Represents 16.0%
Post-BTK disease represents around 16.0% of revenue despite a smaller patient population because treatment is increasingly high value.
Pirtobrutinib, sonrotoclax, Tecartus and Breyanzi all compete directly or indirectly for this population.
Mantle Cell Lymphoma Market Geographical Analysis
North America Leads with 40.2%
North America is estimated to account for 40.2% of global MCL revenue in 2025, equal to about USD 1.01 billion.
The refreshed estimate is close to the 39.3% North American share reported by DataM Intelligence for 2022.
The United States is modeled at 35.2% of worldwide revenue, equal to around USD 883 million.
The U.S. has the broadest current therapeutic menu.
Calquence received frontline approval in January 2025, Breyanzi has been approved since May 2024, Tecartus obtained traditional approval in April 2026 and Beqalzi entered the post-BTK market in May 2026.
Europe Represents 27.4%
Europe is estimated to represent 27.4% of global market revenue, around USD 687 million.
The region became strategically more important following the July 2025 approval of frontline ibrutinib for transplant-eligible patients.
The decision was based on TRIANGLE and supports a transplant-sparing targeted approach.
Germany is modeled at 5.4% of global MCL revenue, reflecting its large hematology market and role in European MCL clinical research.
Asia-Pacific Is the Fastest-Growing Region
Asia-Pacific is estimated to hold 24.2% of global revenue, around USD 607 million, and remains the fastest-growing region consistent with the existing DataM Intelligence outlook.
China is modeled at 6.3% of global MCL revenue.
The country's MCL market has expanded as targeted BTK therapies gain access, while Chinese-origin BTK molecules such as zanubrutinib and orelabrutinib contribute to a growing regional development ecosystem.
BeOne's global MANGROVE study could materially strengthen zanubrutinib's frontline MCL franchise if planned regulatory submissions are successful.
Japan accounts for 4.6% of global revenue, South Korea around 2.8%, India 2.5% and Australia roughly 1.7%.
Latin America Accounts for 4.6%
Latin America represents an estimated 4.6% of global revenue, around USD 115 million.
Brazil is the largest country market, contributing 2.4% of worldwide revenue.
Targeted oral therapies are gradually expanding, but reimbursement and access to CAR-T remain significantly more constrained than in North America.
Middle East & Africa Represent 3.6%
Middle East & Africa account for an estimated 3.6% of global market revenue, USD 90 million.
Saudi Arabia, the UAE and Israel offer the strongest high-value treatment opportunities.
South Africa remains an important specialist hematology market, while access to CAR-T and later-line targeted drugs remains limited across much of the broader region.
All regional and country percentages are DataM Intelligence modeled 2025 revenue estimates unless an existing DMI historical share is explicitly identified.
Mantle Cell Lymphoma Competitive Landscape
AstraZeneca
AstraZeneca has strengthened its MCL position through Calquence/acalabrutinib.
On January 16, 2025, FDA approved Calquence plus bendamustine and rituximab for previously untreated adults who are ineligible for autologous transplant and simultaneously converted its previously treated MCL monotherapy indication to traditional approval.
The ECHO trial's 66.4-month median PFS gives the product a major frontline evidence base.
Johnson & Johnson / AbbVie
J&J and AbbVie jointly commercialize Imbruvica/ibrutinib.
Although MCL use differs by geography, Europe expanded ibrutinib into first-line transplant-eligible disease in July 2025 following TRIANGLE.
The clinical importance lies not simply in adding another indication but in supporting a treatment strategy that can avoid autologous transplantation.
BeOne Medicines
BeOne has become one of the most important emerging MCL competitors.
Brukinsa/zanubrutinib is the company's BTK platform, and MANGROVE produced positive frontline Phase III topline data in June 2026, with a 43% reduction in progression/death risk versus BR.
The company also owns Beqalzi/sonrotoclax, FDA approved in May 2026 for post-BTK relapsed/refractory MCL.
This gives BeOne the potential to compete through both BTK and BCL-2 mechanisms and eventually through combinations of the two.
Gilead / Kite
Gilead's Kite business competes through Tecartus, a CD19-directed CAR-T therapy.
FDA converted Tecartus' MCL indication to traditional approval in April 2026.
The expanded data set strengthens its positioning as CAR-T moves toward earlier relapsed treatment.
Bristol Myers Squibb
BMS competes through Breyanzi, which became a second FDA-approved CAR-T option in MCL in May 2024.
FDA reported an 85.3% response rate and 67.6% complete response rate in the defined efficacy population.
Eli Lilly
Lilly participates through Jaypirca/pirtobrutinib, a non-covalent BTK inhibitor.
The drug is approved under the accelerated pathway for adults with relapsed/refractory MCL after at least two prior systemic therapies including a BTK inhibitor.
Its principal strategic role is extending BTK inhibition beyond covalent-BTK resistance.
Roche
Roche is a major incumbent through rituximab and is developing glofitamab in MCL.
The Phase III GLOBRYTE study remained recruiting in July 2026 and directly compares glofitamab with established relapsed-MCL regimens.
A successful program could introduce an off-the-shelf T-cell-engaging competitor to CAR-T.
Recent Mantle Cell Lymphoma Market Developments
- June 30, 2026: BeOne announced positive Phase III MANGROVE topline results. Zanubrutinib plus rituximab reduced progression/death risk by 43% versus bendamustine-rituximab in untreated MCL, with global regulatory filings planned for the second half of 2026.
- May 13, 2026: FDA granted accelerated approval to Beqalzi/sonrotoclax, the first BCL-2 inhibitor specifically approved for MCL, after prior anti-CD20 and BTK-inhibitor therapy.
- April 1, 2026: FDA converted Tecartus from accelerated to traditional approval in adults with relapsed/refractory MCL.
- July 23, 2025: The European Commission approved an Imbruvica-containing frontline regimen for previously untreated transplant-eligible MCL following TRIANGLE.
- January 16, 2025: FDA approved Calquence plus bendamustine and rituximab for previously untreated transplant-ineligible MCL and granted traditional approval to Calquence monotherapy in previously treated disease.
- May 30, 2024: FDA approved Breyanzi for relapsed/refractory MCL after at least two prior treatment lines including a BTK inhibitor.
Strategic Opportunity Areas Through 2035
Chemotherapy-Free Frontline MCL
MANGROVE provides the most important near-term opportunity.
If zanubrutinib plus rituximab gains approval, first-line treatment could shift toward an oral targeted backbone without bendamustine and without prolonged rituximab maintenance.
MRD-Guided Fixed-Duration Therapy
MRD-negative patients may not require the same treatment intensity as patients with persistent molecular disease.
Current NCI evidence already questions universal transplant in MRD-negative patients, while 2026 trials are directly using ctDNA MRD as a treatment endpoint.
TP53-Directed Treatment
TP53-altered disease remains one of the highest-unmet-need populations.
BTK/BCL-2 combinations, CAR-T and bispecific strategies may eventually become preferred from diagnosis rather than waiting for chemotherapy failure.
Post-BTK Sequencing
The approval of sonrotoclax creates a new decision point after BTK inhibition.
Physicians must increasingly choose among pirtobrutinib, BCL-2 therapy, CAR-T and clinical-trial bispecific therapy based on disease tempo, fitness, center access and previous treatment.
Bispecific Antibodies
Glofitamab could create an important off-the-shelf immune-redirecting market if Phase III GLOBRYTE succeeds.
This would be particularly relevant for patients unable to wait for or access CAR-T manufacturing.
Earlier CAR-T
Tecartus' full approval data support consideration earlier in relapsed disease, while competing CD19 CAR-T therapies create pressure to define optimal timing rather than reserving cellular therapy for very late relapse.
Buyer Value and Strategic Use of the Report
- This refreshed DataM Intelligence analysis positions MCL as an increasingly targeted, biomarker-driven and immune-directed market, rather than the chemotherapy-dominated market represented in older treatment frameworks.
- The report helps buyers distinguish between the commercial roles of frontline covalent BTK inhibition, post-BTK non-covalent therapy, BCL-2 inhibition, CAR-T and emerging bispecific antibodies.
- It also evaluates two developments that could materially alter treatment economics: avoiding autologous transplant in molecular responders and replacing indefinite therapy with MRD-guided fixed-duration combinations.
- Competitive analysis tracks AstraZeneca, J&J/AbbVie, BeOne, Gilead/Kite, BMS, Lilly, and Roche according to treatment line and mechanism rather than presenting them as a single undifferentiated company list.
Target Audience
Pharmaceutical and biotechnology companies, BTK inhibitor developers, BCL-2 inhibitor companies, CAR-T developers, bispecific-antibody companies, lymphoma treatment centers, hematologists, specialty pharmacies, contract research organizations, oncology investors, licensing teams, market-access groups, cell-therapy networks and academic lymphoma research programs.
